Table 1.
Patient characteristics by baseline body mass index (n = 774)
| Characteristic | Body mass index |
P | ||
|---|---|---|---|---|
| Normal | Overweight | Obese | ||
| (n = 202) | (n = 242) | (n = 330) | ||
| Median age (range), y | 57 (23-85) | 56 (34-86) | 56 (28-83) | .76a |
| Age, No. (%), y | .86b | |||
| 20-49 | 52 (25.7) | 61 (25.2) | 80 (24.2) | |
| 50-69 | 127 (62.9) | 154 (63.6) | 220 (66.7) | |
| 70 to ≥80 | 23 (11.4) | 27 (11.2) | 30 (9.1) | |
| Sex, No. (%) | .80c | |||
| Male | 2 (1.0) | 3 (1.2) | 6 (1.8) | |
| Female | 200 (99.0) | 239 (98.8) | 324 (98.2) | |
| Race, No. (%) | .02b | |||
| White | 167 (82.7) | 206 (85.1) | 251 (76.1) | |
| Black | 22 (10.9) | 23 (9.5) | 61 (18.5) | |
| Other/unknown | 13 (6.4) | 13 (5.4) | 18 (5.5) | |
| Taxane as adjuvant therapy, No. (%) | .12b | |||
| Yes | 78 (38.6) | 104 (43.0) | 157 (47.6) | |
| No | 124 (61.4) | 138 (57.0) | 173 (52.4) | |
| Visceral metastases, No. (%) | .93b | |||
| Yes | 159 (79.1) | 193 (80.4) | 262 (79.4) | |
| No | 42 (20.9) | 47 (19.6) | 68 (20.6) | |
| Missing | 1 | 2 | 0 | |
| Disease-free interval, No. (%) | .04b | |||
| 0 (de novo) | 18 (8.9) | 28 (11.6) | 46 (13.9) | |
| <1 y | 44 (21.8) | 39 (16.1) | 77 (23.3) | |
| 1 y < disease-free interval < 2 y | 18 (8.9) | 20 (8.3) | 39 (11.8) | |
| >2 y | 122 (60.4) | 155 (64.0) | 168 (50.9) | |
| Clinical stage, No. (%) | .70b | |||
| Not IV | 20 (11.0) | 20 (9.1) | 27 (8.8) | |
| IV | 162 (89.0) | 199 (90.9) | 281 (91.2) | |
| Missing | 20 | 23 | 22 | |
| Tumor subtype, No. (%) | .51b | |||
| ER and/or PR positive | 153 (75.7) | 178 (73.6) | 235 (71.2) | |
| ER and PR negative | 49 (24.3) | 64 (26.4) | 95 (28.8) | |
| ECOG performance, No. (%) | .04b | |||
| 0 | 116 (57.7) | 164 (68.3) | 193 (58.5) | |
| 1 | 78 (38.8) | 71 (29.6) | 126 (38.2) | |
| Missing | 8 | 7 | 11 | |
a
Two-sided Wilcoxon rank sum test or Kruskal-Wallis test. ECOG = Eastern Cooperative Oncology Group; ER = estrogen receptor; PR = progesterone receptor.
b
Two-sided χ2 test.
c
Two-sided Fisher exact test.